A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Recruiting · NCT07229729 · Interventional (participants receive a specific treatment) · Lead sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
AdebrelimabAlomnertinib MesilateCarboplatinFurmonertini MesilateOsimertinib MesylatePaclitaxelSHR-A2102
What this trial is about
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent form in writing;
- Participants must be aged between 18 and 70 years old (inclusive) when signing the informed consent form, and both men and women are eligible;
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
- Adequate organ function;
- Women of childbearing age must undergo serum pregnancy tests, and the results must be negative. Female subjects of childbearing age and male subjects who are partners of women of childbearing age must agree to use highly effective contraceptive methods.
Exclusion criteria
- With active, known or suspected autoimmune disease of autoimmune disease;
- Malignancies other than NSCLC within 5 years prior to randomization;
- Has or suspected has a history of pneumonitis / interstitial lung disease or any serve lung diseases which will influence the examination of lung function;
- Significant history of cardiovascular and cerebrovascular disease; Significant haemorrhagic disease;
- Has an arteriovenous thrombotic events;
- Has a known history of human immunodeficiency virus (HIV) infection;
- Has a known active Hepatitis B or Hepatitis C;
- Allergic to the intervention regimens.
Where it is running
1 location listed.
- Guangdong Provincial People's Hospital - Guangzhou, Guangdong, China